From the Editor-In-Chief
The U.S. health care system must adapt to the needs of cancer survivors.
by William G. Nelson, MD, PhD
A Matter of Age | Alternatives to Opioids | Treating Head and Neck Skin Cancers | In Women, Lung Cancer Rates Are Rising Worldwide | Breaking Down Breakthrough Cancer Therapies | The Devastating Impact of Muscle Wasting | What’s Next?
Your Cancer Guide
Deciding when and what to worry about can help with gaining control over fear.
by Hester Hill Schnipper
Caregiving with Confidence
Healthy sleep habits should be an important part of self-care for caregivers.
by Aimee Swartz
Let your voice be heard in support of robust, sustained and predictable federal funding increases.
by George D. Demetri, MD
Breast cancer survivor Bob Riter forges connections among people affected by all types of cancer.
by Marci A. Landsmann
New tools are being integrated into the research process to ease patients’ access to clinical trials and improve their experience.
by Bradley Jones
Cancer patients are increasingly receiving treatments guided by the molecular characteristics of their cancer cells. But patients may have unequal access to testing and targeted therapies.
by Kate Yandell
Cancer and its treatment can hinder sexual intimacy, but help is available. Talking about the problem is the first step.
by Cameron Walker
Carb Connection | Make Your Move
Neuroscientist Barbara Lipska describes her experiences with symptoms of psychiatric illness caused by treatment for metastases in her brain.
Experts offer advice on accompanying a friend to a doctor’s appointment, responding to a no evidence of disease diagnosis, and sharing the results of genetic testing.
The End of Treatment Bells fundraiser helps patients mark milestones.
by Sophy Ziss
Readers share snapshots of their lives today.
A proposed federal rule says that patients must be informed after mammograms if they have dense breasts.
by Carly Weeks
Drugs that target DNA repair enzymes may provide alternatives to long-term chemotherapy for some patients with pancreatic cancer.
Survivors and advocates display their posters alongside the work of thousands of cancer researchers.
by Kevin McLaughlin
Drug developers behind the six currently approved checkpoint inhibitors discuss the pros and cons of competition in the field.
A pair of studies demonstrated encouraging clinical outcomes with two different CAR T-cell therapies for patients with advanced solid tumors.
The U.S. Food and Drug Administration has for the first time approved an immunotherapeutic for breast cancer.
Researchers are studying how to treat EGFR-positive non-small cell lung cancer that has become resistant to tyrosine kinase inhibitors.
A Lesson in Service
donate to the AACR